Meeting
2021 ASCO Annual Meeting
Phase I study of LZM005, a HER2 antibody, as monotherapy or in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer.
Authors
Cong Xue
Department of Medical Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
Cong Xue , Herui Yao , Ying Lin , Xin An , Meiting Chen , Yugang Dong , Su Li , Yanxia Shi
Organizations
Department of Medical Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, Sun Yat-sen University Cancer Center, Guangzhou, China, Department of Breast Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
Research Funding
Pharmaceutical/Biotech Company
Livzon Mabpharm Inc, Other Foundation
Background: LZM005 is a novel anti-HER2 antibody that binds with elevated affinity to the domain II of HER2. This phase I study assessed the safety, tolerability, pharmacokinetics (PK) and activity of LZM005, as monotherapy or combined with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer. Methods: The phase I trial included phase Ia and Ib. Phase Ia was the monotherapy dosage escalation design. LZM005 was administered intravenously with 5mg/kg, 10mg/kg, 15mg/kg and 20mg/kg. The endpoints were dose limited toxicity (DLT) and maximum-tolerated dose (MTD), safety, tolerability and PK analysis. In phase Ib, LZM005 was combined with trastuzumab and docetaxel with MTD. The endpoints included safety and tolerability, response, PK and biomarker analysis. Results: From Jan 2017 to Feb 2020, 35 patients received LZM005 (15 monotherapy, 20 combination). No DLT was observed from 5mg/kg to 20mg/kg. In phase Ib two arms were set: 420mg arm and 525mg arm. The pharmacokinetics of LZM005 were similar to pertuzumab (Table). Common adverse events included increased transaminases, diarrhea and anemia in monotherapy and combination therapy. The common AE in phase Ia trial included diarrhea (21.4%), anemia (14.3%), elevated transaminase (14.3%). The common AE in phase Ib trial included anemia (44.1%), diarrhea (41.2%), fatigue (26.5%), elevated transaminases (23.5%), nausea (20.6%), rash (17.6%) and asymptomatic urinary tract infection (11.7%). All adverse events were manageable. No treatment-related death occurred. The clinical benefit rate and objective response rate was respectively 42.90% (6/14) and 7.14% (1/14) with monotherapy, with combination cohort was 100% (8/8) and 62.5% (5/8) in trastuzumab-naive, 83.3% (11/12) and 41.7% (5/12) in trastuzumab-pretreated patients. The median progression free survival was 22.5 weeks. Conclusions: LZM005 was well tolerated and showed potent activity in patients with HER2-positive metastatic breast cancer. Further evaluation was warranted. Clinical trial information: CTR20191921.
| Group | average±SD (%CV) | |||
|---|---|---|---|---|
| 5 mg/kg (N=1) | 10 mg/kg (N=4) | 15 mg/kg (N=3) | 20 mg/kg (N=6) | |
| AUC 0-21d(h*μg/ml) | 22598.296±-(-) | 37026.958±6856.2857(18.517) | 57284.723±4943.5427(8.63) | 59894.118±13138.0635(21.935) |
| Cmax (µg/ml) | 132.385±-(-) | 219.402±39.0606(17.803) | 345.502±36.8012(10.652) | 340.037±40.5673(11.930) |
| t1/2(h) | 211.122±-(-) | 374.983±63.2312(16.862) | 244.263±57.0101(23.34) | 215.294±72.6508(33.745) |
| CL(ml/h) | 10.433±-(-) | 8.989±2.1178 (23.56) | 11.576±3.8161(32.965) | 16.279±5.4647 (33.568) |
| Vss(ml) | 3382.474±-(-) | 4508.610±430.9516(9.558) | 3708.281±354.6646(9.564) | 4609.199±599.7108(13.011) |
| Vz(ml) | 2922.609±-(-) | 4543.860±349.47 (7.691) | 3855.877±770.0037(19.970) | 4537.133±733.7645(16.172) |
| Ctrough(mg/ml) | 0±-(-) | 0±-(-) | 0±-(-) | 0±-(-) |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
CTR20191921
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 1042)
DOI
10.1200/JCO.2021.39.15_suppl.1042
Abstract #
1042
Poster Bd #
Online Only
Abstract Disclosures
Similar Abstracts
First Author: Nicholas Patrick McAndrew
Abstract
2018 ASCO Annual Meeting
A phase I study of a PD-L1 antibody (Durvalumab) in combination with trastuzumab in HER-2 positive metastatic breast cancer (MBC) progressing on prior anti HER-2 therapies (CCTG IND.229)[NCT02649686].
First Author: Stephen K. L. Chia
Abstract
2022 ASCO Annual Meeting
Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with PIK3CA-mutated, hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC).
First Author: Philippe L. Bedard
Abstract
2024 ASCO Annual Meeting
An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, and pharmacokinetics of VIP236 monotherapy in patients with advanced cancer.
First Author: Andrae L. Vandross